Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Retinitis Pigmentosa: early-phase trial registry
15 of 38 indexed Retinitis Pigmentosa trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #393 of 28,707 conditions by registered trial count.
38 US clinical trials · 15 currently recruiting · #393 of 28,707 conditions by registered trial count
Retinitis Pigmentosa: 38 US clinical trials tracked, 15 recruiting.
Retinitis Pigmentosa is the subject of 38 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is National Eye Institute (NEI), running 4 of these trials.
Enrollment posture brief
Registry condition retinitis-pigmentosa
OPEN 15 | RECR 39% | LATE 2 | EARLY 14 | RANK #393 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Squamous Cell Carcinoma of Head and Neck (39% recruiting · 38 trials)
Retinitis Pigmentosa lists 15 open slots (39% of 38 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Retinitis Pigmentosa on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Retinitis Pigmentosa recruits in line with its size-band peers.
15 of 38 indexed trials (39.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Retinitis Pigmentosa trials is spread across many organizations.
National Eye Institute (NEI) accounts for 4 of 38 trials (10.5%). 25 distinct sponsors appear on at least one study for this condition label.
-
Most Retinitis Pigmentosa trials plan to enrol fewer than 100 people.
Median target enrolment is 35 among the 38 trials that report a genuine target (sentinel values excluded). 26 of those (68.4%) plan for fewer than 100 participants.
-
Retinitis Pigmentosa splits between interventional and observational designs.
23 interventional and 15 observational studies make up this index (60.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
38 total, page 1 of 1
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
Jaeb Center for Health Research
NCT05589714
Cell Collection to Study Eye Diseases
National Eye Institute (NEI)
NCT01432847
High Resolution Retinal Imaging
University of Pennsylvania
NCT01866371
Stem Cell Ophthalmology Treatment Study II
MD Stem Cells
NCT03011541
Rod and Cone Mediated Function in Retinal Disease
National Eye Institute (NEI)
NCT02617966
Retinal Imaging in Patients With Inherited Retinal Degenerations
University of California, San Francisco
NCT00254605
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
Ray Therapeutics
NCT06375239
Adaptive Optics Imaging of Outer Retinal Diseases
Food and Drug Administration (FDA)
NCT05355415
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
jCyte
NCT06912633
Study of BEST1 Vitelliform Macular Dystrophy
Columbia University
NCT05809635
Promising ROd-cone DYstrophy Gene therapY
SparingVision
NCT05748873
BS01 in Patients With Retinitis Pigmentosa
Bionic Sight
NCT04278131
Experimental and Clinical Studies of Retinal Stimulation
University of Michigan
NCT03635645
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
University of Rochester
NCT06319872
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
Sumitomo Pharma America
NCT06891885
Oral N-acetylcysteine for Retinitis Pigmentosa
Johns Hopkins University
NCT05537220
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
Ocugen
NCT06388200
Rate of Progression in EYS Related Retinal Degeneration
Jaeb Center for Health Research
NCT04127006
Prospective Natural History Study of Retinitis Pigmentosa
SparingVision
NCT04285398
Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
PYC Therapeutics
NCT05573984
Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F
Jaeb Center for Health Research
NCT04765345
FIGHT-RP 1 Extension Study
Johns Hopkins University
NCT03999021
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
Ocugen
NCT05203939
Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa
Nova Southeastern University
NCT02086890
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
Nanoscope Therapeutics
NCT06162585
CNS10-NPC for the Treatment of RP
Cedars-Sinai Medical Center
NCT04284293
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
University of California, Davis
NCT01736059
A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)
Sumitomo Pharma America
NCT06517940
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
Ray Therapeutics
NCT06460844
Molecular Genetics of Retinal Degenerations
National Eye Institute (NEI)
NCT00231010
Trial of Oral Valproic Acid for Retinitis Pigmentosa
Foundation Fighting Blindness
NCT01233609
Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT
Nanoscope Therapeutics
NCT05820100
Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
jCyte
NCT04604899
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
Nanoscope Therapeutics
NCT04945772
Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
National Eye Institute (NEI)
NCT00065455
Object Finder for a Retinal Prosthesis
Minnesota HealthSolutions
NCT04319809
Argus II/ORCAM Device Study
Mayo Clinic
NCT03248388
Computer-Assisted Rehabilitation Environment Training After Argus Retinal Prosthesis
The Cleveland Clinic
NCT03444961
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 4 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Retinitis Pigmentosa records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Retinitis Pigmentosa trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Retinitis Pigmentosa page
38 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Retinitis Pigmentosa trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Eye Institute (NEI) sponsors the most Retinitis Pigmentosa trials on record, review their full trial history before evaluating a specific study. See National Eye Institute (NEI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Retinitis Pigmentosa condition card totals 38 registered trials; most-linked intervention human retinal progenitor cells; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.